NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis $88.49 -0.50 (-0.56%) (As of 11:07 AM ET) Add Compare Share Share Today's Range$87.99▼$89.1750-Day Range$78.36▼$96.0052-Week Range$76.53▼$125.83Volume57,651 shsAverage Volume701,021 shsMarket Capitalization$21.04 billionP/E Ratio176.98Dividend YieldN/APrice Target$109.09 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BioNTech alerts: Email Address BioNTech MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside23.2% Upside$109.09 Price TargetShort InterestHealthy1.32% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.08Based on 32 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.04) to ($2.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.06 out of 5 starsMedical Sector581st out of 924 stocksBiological Products, Except Diagnostic Industry89th out of 145 stocks 3.3 Analyst's Opinion Consensus RatingBioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageBioNTech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioNTech's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.32% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in BioNTech has recently decreased by 6.82%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of BioNTech is 306.00%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about BioNTech's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTX. Previous Next 2.3 News and Social Media Coverage News SentimentBioNTech has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 32 news articles for BioNTech this week, compared to 9 articles on an average week.Search InterestOnly 17 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat Follows7 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.52% of the stock of BioNTech is held by institutions.Read more about BioNTech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioNTech are expected to decrease in the coming year, from ($2.04) to ($2.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 177.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 145.04.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 177.10, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 139.34.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioNTech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. Click here to get details on this opportunity now. About BioNTech Stock (NASDAQ:BNTX)BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More BNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTX Stock News HeadlinesAugust 19 at 11:52 AM | marketbeat.comModerna Dips on Q2 Earnings But Can It Rip on a Short Squeeze? (BNTX)Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.August 12, 2024 | marketbeat.comNovavax Plunges on Earnings Miss: Falling Knife or Buying Opp? (BNTX)Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases.August 22, 2024 | DTI (Ad)Air Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.August 21 at 1:20 AM | americanbankingnews.comBioNTech SE Forecasted to Earn Q3 2024 Earnings of $0.85 Per Share (NASDAQ:BNTX)August 20 at 5:26 PM | seekingalpha.comBioNTech: Clinical Hold Removal Pushes ADC Development Program ForwardAugust 20 at 8:40 AM | americanbankingnews.comBioNTech SE (NASDAQ:BNTX) Short Interest UpdateAugust 20 at 5:02 AM | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for BioNTech (NASDAQ:BNTX)August 19 at 9:25 PM | msn.comFDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower DoseAugust 22, 2024 | DTI (Ad)Air Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.August 19 at 9:25 PM | benzinga.comUnveiling 12 Analyst Insights On BioNTechAugust 19 at 9:25 PM | marketwatch.comBioNTech SE ADR rises Monday, outperforms marketAugust 19 at 4:07 AM | fool.comPfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?August 19 at 1:30 AM | americanbankingnews.comBioNTech SE (NASDAQ:BNTX) Receives Average Rating of "Moderate Buy" from BrokeragesAugust 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioNTech Amidst Flu/COVID Vaccine Potential and Strong Oncology PipelineAugust 17, 2024 | americanbankingnews.comBioNTech (NASDAQ:BNTX) Shares Gap Down After Analyst DowngradeAugust 16, 2024 | finance.yahoo.comPfizer and BioNTech’s Covid-19/flu combination vaccine falters in Phase III readoutAugust 16, 2024 | marketwatch.comBioNTech SE ADR falls Friday, underperforms marketAugust 16, 2024 | finance.yahoo.comPfizer, BioNTech stumble in effort to develop combination flu, COVID shotSee More Headlines Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today8/22/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees6,133Year Founded2008Price Target and Rating Average Stock Price Target$109.09 High Stock Price Target$171.00 Low Stock Price Target$85.00 Potential Upside/Downside+22.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$0.50 Trailing P/E Ratio177.98 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.01 billion Net Margins4.01% Pretax Margin5.55% Return on Equity0.55% Return on Assets0.49% Debt Debt-to-Equity Ratio0.01 Current Ratio11.38 Quick Ratio11.16 Sales & Book Value Annual Sales$2.69 billion Price / Sales7.86 Cash Flow$5.59 per share Price / Cash Flow15.91 Book Value$92.17 per share Price / Book0.97Miscellaneous Outstanding Shares237,726,000Free Float192,083,000Market Cap$21.16 billion OptionableOptionable Beta0.23 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Ugur Sahin M.D. (Age 59)Co-Founder, CEO & Chair of the Management Board Comp: $1.25MDr. Ozlem Tureci M.D. (Age 57)Co-Founder, Chief Medical Officer & Member of Management Board Comp: $823.67kMr. Jens H. Holstein (Age 61)CFO & Member of Management Board Comp: $1.44MDr. Sierk Poetting Ph.D. (Age 51)MD, COO & Member of Management Board Comp: $846.46kMr. Ryan Richardson (Age 45)Chief Strategy Officer, MD & Member of Management Board Comp: $1.04MMr. Sean Marett (Age 59)Chief Business Officer, Chief Commercial Officer & Member of Management Board Comp: $817.16kDr. James Timothy Patrick Ryan Ph.D. (Age 49)Chief Legal Officer & Member of the Management Board Comp: $612.05kMr. Zach TaylorSenior Vice President of Corporate Development & StrategyDr. Katalin Kariko Ph.D.Senior VP & External Consultant for RNA Protein Replacement TherapiesDr. Oliver Henning Ph.D.Senior Vice President of OperationsMore ExecutivesKey CompetitorsTakeda PharmaceuticalNYSE:TAKModernaNASDAQ:MRNATeva Pharmaceutical IndustriesNYSE:TEVABeiGeneNASDAQ:BGNEGenmab A/SNASDAQ:GMABView All CompetitorsInstitutional OwnershipGranite Bay Wealth Management LLCBought 18,459 shares on 8/21/2024Ownership: 0.008%Truist Financial CorpSold 678 shares on 8/21/2024Ownership: 0.007%Employees Retirement System of TexasBought 4,115 shares on 8/15/2024Ownership: 0.013%Millennium Management LLCSold 2,800 shares on 8/15/2024Ownership: 0.000%Caxton Associates LPBought 8,485 shares on 8/15/2024Ownership: 0.004%View All Institutional Transactions BNTX Stock Analysis - Frequently Asked Questions How have BNTX shares performed this year? BioNTech's stock was trading at $105.54 at the beginning of 2024. Since then, BNTX shares have decreased by 16.1% and is now trading at $88.55. View the best growth stocks for 2024 here. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) announced its quarterly earnings data on Monday, August, 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.02) by $1.34. The company's quarterly revenue was down 23.3% compared to the same quarter last year. What is Ugur Sahin's approval rating as BioNTech's CEO? 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend. Does BioNTech have any subsidiaries? The following companies are subsidiaries of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and others. When did BioNTech IPO? BioNTech (BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? Top institutional investors of BioNTech include Baillie Gifford & Co. (3.48%), Primecap Management Co. CA (2.01%), Deerfield Management Company L.P. Series C (0.25%) and Candriam S.C.A. (0.24%). How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX) and Gilead Sciences (GILD). This page (NASDAQ:BNTX) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BNTX Stock Alerts